[The national registry EVASTENT: cost-effectiveness analysis of the sirolimus active stent in diabetic and non-diabetic patients]

Ann Cardiol Angeiol (Paris). 2004 May:53 Suppl 1:22s-28s. doi: 10.1016/s0003-3928(04)90005-4.
[Article in French]
No abstract available

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Combined Modality Therapy
  • Coronary Stenosis / economics*
  • Coronary Stenosis / therapy*
  • Cost-Benefit Analysis
  • Diabetes Complications / economics*
  • Diabetes Complications / therapy*
  • Drug Delivery Systems / economics*
  • Female
  • Follow-Up Studies
  • Humans
  • Immunosuppressive Agents / administration & dosage*
  • Immunosuppressive Agents / economics*
  • Male
  • Middle Aged
  • Registries*
  • Sirolimus / administration & dosage*
  • Sirolimus / economics*
  • Stents / economics*
  • Surveys and Questionnaires

Substances

  • Immunosuppressive Agents
  • Sirolimus